ReviewExpert opinion on drug delivery2014
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer.
Review in Expert opinion on drug delivery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Bimodal nanobody agents for cancer imaging and potential intraoperative guidance: a systematic review.Journal of nanobiotechnology · 2026Pooled it
- Anti-HER2 nanobody 5F7-based theranostics using [European journal of nuclear medicine and molecular imaging · 2026Article
- Head-to-head comparison of FAP-targeting single-domain antibody 4AH29 vs. peptide FAP-2286.EJNMMI research · 2026Article
- Affinity- and Format-Dependent Pharmacokinetics ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Advancements in Targeted Radiopharmaceuticals: Innovations in Diagnosis and Therapy for Enhanced Cancer Management.Chembiochem : a European journal of chemical biology · 2026Review
- Efficient α and βEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Utility ofInternational journal of nanomedicine · 2025Article
- CD38 as theranostic target in oncology.Journal of translational medicine · 2024Review
- Sortase-Mediated Site-Specific Conjugation to Prepare Fluorine-18-Labeled Nanobodies.Bioconjugate chemistry · 2024Article
- Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.International journal of molecular sciences · 2024Article
- Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation.European journal of medical research · 2024Review
- Review
- Single domain Camelid antibody fragments for molecular imaging and therapy of cancer.Frontiers in oncology · 2023Review
- Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens.Theranostics · 2023Review
- Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.Theranostics · 2023Article
- Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Emerging Trends in Immunotherapy for Cancer.Diseases (Basel, Switzerland) · 2022Review
- Matrices and Affinity Ligands for Antibody Purification and Corresponding Applications in Radiotherapy.Biomolecules · 2022Review
- Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.EJNMMI research · 2022Review
- Radiotheranostic Agents in Hematological Malignancies.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe integration of diagnostic testing for the presence of a molecular target is of interest to predict successful targeted radionuclide therapy (TRNT). This so-called 'theranostic' approach aims to improve personalized treatment based on the molecular characteristics of cancer cells. Moreover, it offers new insights in predicting adverse effects and provides appropriate tools to monitor therapy responses. Recent findings using nanobodies emphasize their potential as theranostic tools in cancer treatment. Nanobodies are recombinant, small antigen-binding fragments that are derived from camelid heavy-chain-only antibodies. AREAS COVERED: We review the current status of theranostic approaches in TRNT, with a focus on antibodies, peptides, scaffold proteins and emerging nanobodies. In recent years, nanobodies have been evaluated intensively for molecular imaging. In addition, novel data on TRNT using radiolabeled nanobodies for carcinomas and multiple myeloma highlight their promising opportunities in cancer treatment. EXPERT OPINION: We trust that radiolabeled nanobodies will have a future potential as theranostic tools in cancer therapy, both for diagnosis as well as for TRNT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.